Pioneering Autoimmune CAR-T Therapy Expert, Internationally Renowned Rheumatologist Prof. Georg Schett Joins MagicRNA Bio’s Advisory Committee as Chief Medical Advisor

In May 2025, Prof. Georg Schett, a pioneer in autoimmune CAR-T therapy and a globally renowned rheumatologist, officially joined MagicRNA Bio’s Advisory Committee as Chief Medical Advisor. As a leading medical expert who first applied autologous CAR-T cell therapy to treat refractory autoimmune diseases and continues to drive clinical research and innovation in this field, Prof. Schett will guide MagicRNA Bio in clinical research, pipeline development, and FDA communications, accelerating the clinical translation of In Vivo CAR-T therapies.

Prof. Georg Schett currently serves as Vice President of Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Director of the Department of Rheumatology and Immunology at Universitätsklinikum Erlangen. He also holds key positions in prestigious international academic organizations, including the American College of Rheumatology (ACR), the American Society for Bone and Mineral Research (ASBMR), and the European Alliance of Associations for Rheumatology (EULAR). As a global leader in rheumatology and immunology, Prof. Schett has received numerous top-tier academic awards, including the Bilroth Prize, ESCI Prize, and Carol-Nachmann Prize. His research team has been awarded major grants such as the German DAdorw and DVO, with cumulative research funding exceeding tens of millions of euros. To date, he has published over 1,000 papers in leading international journals such as NEJM, Lancet, JAMA, Nature, Nature Medicine, Nature Immunology, and Immunity, with an outstanding H-index of 155. He has been invited to deliver over 800 keynote speeches at major global academic conferences.

In August 2021, Prof. Schett’s team published a groundbreaking study in the New England Journal of Medicine (NEJM) reporting the successful use of CD19 CAR-T cell therapy in a 20-year-old female patient with refractory systemic lupus erythematosus (SLE). The treatment rapidly induced disease remission, achieving a complete drug-free remission state with no significant side effects. This patient was the first SLE patient in the world to receive CAR-T cell therapy, and as of now, she remains relapse-free.

In September 2022, Prof. Schett’s team published another milestone study in Nature Medicine, reporting five refractory SLE patients (four females and one male, average age 22) treated with CAR-T cell therapy. All patients showed significant improvement, with no relapses during a 17-month follow-up, and all achieved drug-free remission.

In March 2023, Prof. Schett published a case study in The Lancet demonstrating the first successful use of CAR-T cell therapy in a male patient with severe anti-synthetase syndrome (ASS), a challenging autoimmune disease. Six months post-treatment, the patient achieved complete recovery and no longer required immunosuppressive drugs. This marked the world’s first successful CAR-T therapy for ASS and the second autoimmune disease cured by CAR-T after SLE.

MagicRNA Bio stated:“Prof. Schett’s joining is a strong endorsement of our technological platform and R&D capabilities. We will leverage his profound academic expertise and extensive clinical research experience to accelerate the development of innovative therapies for autoimmune diseases. This collaboration combines MagicRNA Bio’s strengths in cutting-edge biotechnology with Prof. Schett’s clinical research leadership, expediting the clinical validation of our HN2301 pipeline to bring more effective treatment options to global autoimmune disease patients.”

About MagicRNA Bio:
Shenzhen MagicRNA Bio (founded in 2021) is committed to advancing RNA drug delivery technologies to benefit patients through RNA therapeutics. The company has developed China’s largest ionizable amino lipid library, with its core lipid (ILB3132) already commercialized. Addressing the industry-wide challenge of extrahepatic and non-APC-targeted mRNA delivery, MagicRNA Bio successfully established its Engineered Cell-Targeted LNP (EnC-LNP) platform in 2022, achieving world-leading efficiency in engineering and targeted delivery, providing robust support for precise nucleic acid drug delivery.Based on the EnC-LNP platform, MagicRNA Bio’s In Vivo CAR-T pipeline (HN2301) achieved the world’s first First-in-Human (FIH) clinical trial in Q1 2025, pioneering the frontier of cell-targeted LNP applications in autoimmune diseases.